Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of m...

Sangfor Technologies, a leading global vendor of IT infrastructure and Security solutions, is proud to announce a new Global Strategic Partnership with Cohesity, the leader in AI-powered data security. Under this new partnership, Sangfor has officially joined the Cohesity Aspire Managed Service Provider (MSP) Program, enabling Sangfor to provide enterprise‑grade business resilience solutions with Cohesity, including the resale of their products, worldwide, for the first time. This partnership...

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Sub...